Do analysts prefer CRVO or MENS?

CervoMed currently has a consensus price target of $21.00, indicating a potential upside of 707.69%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, CRVO or MENS?

Jyong Biotech has lower revenue, but higher earnings than CervoMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed $4.01M 9.80 -$26.97M -$3.22 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is CRVO or MENS more profitable?

Jyong Biotech has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Jyong Biotech's return on equity of 0.00% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed -672.80% -156.02% -128.34% Jyong Biotech N/A N/A N/A

CervoMed (CRVO) Competitors

$2.60 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

CRVO vs. UNCY, LENZ, MENS, AARD, and MIST

Should you buy CervoMed stock or one of its competitors? CervoMed's main competitors and comparable companies include Unicycive Therapeutics (UNCY), LENZ Therapeutics (LENZ), Jyong Biotech (MENS), Aardvark Therapeutics (AARD), and Milestone Pharmaceuticals (MIST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CervoMed compare to Unicycive Therapeutics?

CervoMed (NASDAQ:CRVO) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

CervoMed has a beta of -0.63, suggesting that its share price is 163% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

In the previous week, CervoMed and CervoMed both had 1 articles in the media. CervoMed's average media sentiment score of 1.87 equaled Unicycive Therapeutics'average media sentiment score.

Company	Overall Sentiment
CervoMed	Very Positive
Unicycive Therapeutics	Very Positive

CervoMed presently has a consensus price target of $21.00, suggesting a potential upside of 707.69%. Unicycive Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 256.46%. Given CervoMed's stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

25.2% of CervoMed shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Unicycive Therapeutics' return on equity of -91.50% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Unicycive Therapeutics has lower revenue, but higher earnings than CervoMed. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.80	-$26.97M	-$3.22	N/A
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$1.75	N/A

Summary

Unicycive Therapeutics beats CervoMed on 8 of the 14 factors compared between the two stocks.

How does CervoMed compare to LENZ Therapeutics?

CervoMed (NASDAQ:CRVO) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

CervoMed has a beta of -0.63, meaning that its stock price is 163% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

25.2% of CervoMed shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 35.8% of CervoMed shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LENZ Therapeutics has a net margin of -586.74% compared to CervoMed's net margin of -672.80%. LENZ Therapeutics' return on equity of -53.39% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

CervoMed has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.80	-$26.97M	-$3.22	N/A
LENZ Therapeutics	$21.48M	7.48	-$82.13M	-$4.09	N/A

CervoMed currently has a consensus target price of $21.00, indicating a potential upside of 707.69%. LENZ Therapeutics has a consensus target price of $28.80, indicating a potential upside of 463.60%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, LENZ Therapeutics had 5 more articles in the media than CervoMed. MarketBeat recorded 6 mentions for LENZ Therapeutics and 1 mentions for CervoMed. CervoMed's average media sentiment score of 1.87 beat LENZ Therapeutics' score of 1.04 indicating that CervoMed is being referred to more favorably in the media.

Company	Overall Sentiment
CervoMed	Very Positive
LENZ Therapeutics	Positive

Summary

CervoMed beats LENZ Therapeutics on 9 of the 17 factors compared between the two stocks.

How does CervoMed compare to Jyong Biotech?

CervoMed (NASDAQ:CRVO) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

CervoMed has a beta of -0.63, indicating that its share price is 163% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

25.2% of CervoMed shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Jyong Biotech has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Jyong Biotech's return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-156.02%	-128.34%
Jyong Biotech	N/A	N/A	N/A

Jyong Biotech has lower revenue, but higher earnings than CervoMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.80	-$26.97M	-$3.22	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

In the previous week, CervoMed and CervoMed both had 1 articles in the media. Jyong Biotech's average media sentiment score of 1.89 beat CervoMed's score of 1.87 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
CervoMed	Very Positive
Jyong Biotech	Very Positive

CervoMed currently has a consensus price target of $21.00, indicating a potential upside of 707.69%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CervoMed beats Jyong Biotech on 7 of the 13 factors compared between the two stocks.

How does CervoMed compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

CervoMed has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
CervoMed	$4.01M	9.80	-$26.97M	-$3.22	N/A

Aardvark Therapeutics has a beta of 3.81, meaning that its stock price is 281% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, meaning that its stock price is 163% less volatile than the broader market.

Aardvark Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Aardvark Therapeutics' return on equity of -71.54% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
CervoMed	-672.80%	-156.02%	-128.34%

Aardvark Therapeutics presently has a consensus target price of $15.33, suggesting a potential upside of 164.82%. CervoMed has a consensus target price of $21.00, suggesting a potential upside of 707.69%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Aardvark Therapeutics had 30 more articles in the media than CervoMed. MarketBeat recorded 31 mentions for Aardvark Therapeutics and 1 mentions for CervoMed. CervoMed's average media sentiment score of 1.87 beat Aardvark Therapeutics' score of 0.04 indicating that CervoMed is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
CervoMed	Very Positive

25.2% of CervoMed shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by insiders. Comparatively, 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CervoMed beats Aardvark Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CervoMed compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 35.8% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Milestone Pharmaceuticals currently has a consensus price target of $6.40, suggesting a potential upside of 451.72%. CervoMed has a consensus price target of $21.00, suggesting a potential upside of 707.69%. Given CervoMed's higher probable upside, analysts clearly believe CervoMed is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Milestone Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, meaning that its share price is 163% less volatile than the broader market.

Milestone Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -156.02% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
CervoMed	-672.80%	-156.02%	-128.34%

In the previous week, Milestone Pharmaceuticals had 3 more articles in the media than CervoMed. MarketBeat recorded 4 mentions for Milestone Pharmaceuticals and 1 mentions for CervoMed. CervoMed's average media sentiment score of 1.87 beat Milestone Pharmaceuticals' score of 0.72 indicating that CervoMed is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Positive
CervoMed	Very Positive

CervoMed has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	93.17	-$63.06M	-$0.69	N/A
CervoMed	$4.01M	9.80	-$26.97M	-$3.22	N/A

Summary

Milestone Pharmaceuticals and CervoMed tied by winning 7 of the 14 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVO vs. The Competition

Export

Metric	CervoMed	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.31M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-0.81	787.65	273.16	25.42
Price / Sales	9.80	760.15	635.16	104.14
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	1.32	10.49	11.08	6.36
Net Income	-$26.97M	$2.83B	$3.48B	$349.79M
7 Day Performance	-1.14%	0.58%	0.38%	-0.40%
1 Month Performance	0.78%	5.69%	7.89%	4.24%
1 Year Performance	-72.97%	6.19%	24.71%	15.13%

CervoMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVO CervoMed	3.8206 of 5 stars	$2.60 flat	$21.00 +707.7%	-73.0%	$39.31M	$4.01M	N/A	4	Positive News
UNCY Unicycive Therapeutics	3.2117 of 5 stars	$5.65 +1.3%	$18.25 +223.3%	+25.5%	$156.94M	$680K	N/A	9	Positive News Gap Up
LENZ LENZ Therapeutics	3.3539 of 5 stars	$4.82 +0.6%	$28.80 +497.5%	-86.8%	$152.39M	$19.09M	N/A	110	Positive News
MENS Jyong Biotech	N/A	$2.00 -0.7%	N/A	-95.7%	$151.68M	N/A	N/A	31	Positive News
AARD Aardvark Therapeutics	2.8451 of 5 stars	$6.12 -9.2%	$16.30 +166.5%	-30.2%	$133.95M	N/A	N/A	18	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVO) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Competitors

CRVO vs. UNCY, LENZ, MENS, AARD, and MIST

How does CervoMed compare to Unicycive Therapeutics?

Summary

How does CervoMed compare to LENZ Therapeutics?

Summary

How does CervoMed compare to Jyong Biotech?

Summary

How does CervoMed compare to Aardvark Therapeutics?

Summary

How does CervoMed compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CervoMed (CRVO) Competitors

CRVO vs. UNCY, LENZ, MENS, AARD, and MIST

How does CervoMed compare to Unicycive Therapeutics?

Which has more risk and volatility, CRVO or UNCY?

Does the media prefer CRVO or UNCY?

Do analysts prefer CRVO or UNCY?

Do insiders and institutionals hold more shares of CRVO or UNCY?

Is CRVO or UNCY more profitable?

Which has better earnings and valuation, CRVO or UNCY?

Summary

How does CervoMed compare to LENZ Therapeutics?

Which has more volatility & risk, CRVO or LENZ?

Do institutionals & insiders have more ownership in CRVO or LENZ?

Is CRVO or LENZ more profitable?

Which has better valuation & earnings, CRVO or LENZ?

Do analysts recommend CRVO or LENZ?

Does the media prefer CRVO or LENZ?

Summary

How does CervoMed compare to Jyong Biotech?

Which has more volatility & risk, CRVO or MENS?

Do institutionals and insiders have more ownership in CRVO or MENS?

Is CRVO or MENS more profitable?

Which has better earnings & valuation, CRVO or MENS?

Does the media refer more to CRVO or MENS?

Do analysts prefer CRVO or MENS?

Summary

How does CervoMed compare to Aardvark Therapeutics?

Which has stronger earnings and valuation, AARD or CRVO?

Which has more risk and volatility, AARD or CRVO?

Is AARD or CRVO more profitable?

Do analysts prefer AARD or CRVO?

Does the media favor AARD or CRVO?

Do insiders and institutionals hold more shares of AARD or CRVO?

Summary

How does CervoMed compare to Milestone Pharmaceuticals?

Do insiders & institutionals hold more shares of MIST or CRVO?

Do analysts rate MIST or CRVO?

Which has more volatility and risk, MIST or CRVO?

Is MIST or CRVO more profitable?

Does the media favor MIST or CRVO?

Which has better valuation and earnings, MIST or CRVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools